Profile of Afatinib and its Potential in the Treatment of Head and Neck Cancer: Current EvidenceDenaro N* and Merlano MC
Department of Clinical Oncology S. Croce University Hospital, Cuneo, Italy
- *Corresponding Author:
- Denaro N
Department of Clinical Oncology
S. Croce University Hospital, Cuneo, Italy
E-mail: [email protected] hotmail.com
Received date: September 16, 2015 Accepted date: October 27, 2015 Published date: November 4, 2015
Citation: Denaro N, Merlano MC (2015) Profile of Afatinib and its Potential in the Treatment of Head and Neck Cancer: Current Evidence. Oncol Trans Res 1:101. doi:10.4172/JOTR.1000101
Copyright: © 2015 Denaro N et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. About two thirds of patients present with locally advanced disease (LAHNC) (stage III e IV) in this setting a multidisciplinary approach is complex and evolving. In Recurrent/metastatic (R/M) HNSCC, Cetuximab, a monoclonal antibody against EGFR plus platinum - based chemotherapy (CT) allow overall survival (OS) of about 10 months. However prognosis for R/M-HNSCC remains dismal and additional efforts are needed. Currently no standard second line treatment may be offered to R/M HNSCC. Recent molecular breakthroughs in HNSCC and the use of new targeted therapies provide much hope for future strategies. Promising activity has been shown by target therapies beyond Cetuximab. Afatinib an irreversible inhibitor of the tyrosine kinase activity of EGFR family represents a promising drug to after first line failure and to overcome Cetuximab resistance.